Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.43 |
| ▸ | RAF1 | P04049 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.43 |
| ▸ | KRAS | P01116 | 3/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.43 |
| ▸ | ARAF | P10398 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.37 |
| ▸ | FLT1 | P17948 | 9/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.37 |
| ▸ | FLT4 | P35916 | 9/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632379 | 0.86 | KDR (0.46) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL16632590 | 0.86 | KDR (0.51) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL15289592 | 0.85 | BRAF (0.38) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL15289552 | 0.82 | BRAF (0.56) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL16632504 | 0.81 | KDR (0.53) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL16632291 | 0.79 | HDAC1 (0.42) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL15289636 | 0.77 | BRAF (0.65) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL16632254 | 0.77 | BRAF (0.65) | KDRRAF1BRAFKRASMAP2K2 | |
| SCHEMBL15289708 | 0.77 | BRAF (0.57) | KDRRAF1BRAFKRASMAP2K2 | |
| Hydrochloric Acid SCHEMBL16632446 | 0.76 | BRAF (0.56) | KDRRAF1BRAFKRASMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187474-B2 | Raf inhibitor compounds | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150105367-A1 | RAF INHIBITOR COMPOUNDS | DECIPHERA PHARMACEUTICALS, LLC | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105367-A1 | RAF INHIBITOR COMPOUNDS | BRAF, RAF1, NRAS | KDR 806/4885RAF1 2/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.